1.535

1.66% 0.025

Enveric Biosciences Inc (ENVB)

Overview News Price History Financials Discussions Forecast Stock Split Dividend History

Enveric Biosciences Inc stock is traded at $1.535, with a volume of 55,643. It is up +1.66% in the last 24 hours and up +16.29% over the past month. Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Previous Close:

$1.51

Open:

$1.53

24h Volume:

55,643

Relative Volume:

0.34

Market Cap:

$6.18M

Revenue:

Net Income/Loss:

$-8.22M

P/E Ratio:

-0.0561

EPS:

-27.3467

Net Cash Flow:

$-8.01M

1W Performance:

-0.97%

1M Performance:

+16.29%

6M Performance:

-26.90%

1Y Performance:

-88.48%

1-Day Range:

$1.45

$1.57

1-Week Range:

$1.45

$1.62

52-Week Range:

$1.25

$17.64

Enveric Biosciences Inc Stock (ENVB) Company Profile

Name

Enveric Biosciences Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(617) 444-8400

Address

245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

ENVB's Discussions on Twitter

Compare ENVB vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENVB Enveric Biosciences Inc	1.535	6.24M	0	-8.22M	-8.01M	-27.35
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Enveric Biosciences Inc Stock (ENVB) Latest News

Aug 14, 2026

Form 8K Enveric Biosciences Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Enveric Biosciences Posts $3.0 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 14, 2026

Enveric Biosciences (NASDAQ: ENVB) deepens Q2 loss while pushing EB-003 toward trials - Stock Titan

Aug 14, 2026

Enveric Biosciences (ENVB) holders Lind entities report 1.3–1.4% warrant-based stake - Stock Titan

Aug 14, 2026

Enveric's EB-003 Shows Non-Hallucinogenic Profile in Preclinical Data - Stock Titan

Aug 14, 2026

Armistice Capital (ENVB) discloses 405,092-share position in Enveric Biosciences - Stock Titan

Aug 14, 2026

Aug 13, 2026

Enveric Biosciences (ENVB) investors disclose 2.93% stake via 111,145-share warrants - Stock Titan

Aug 13, 2026

Aug 11, 2026

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits

Aug 11, 2026

Aug 07, 2026

Enveric Biosciences Inc (NASDAQ: ENVB) Share Price, ENVB Stock News, ENVB Share Price & Updates - Kalkine

Aug 07, 2026

Aug 05, 2026

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Ca - benzinga.com

Aug 05, 2026

Enveric reports preclinical data on EB-003 drug candidate By Investing.com - Investing.com Canada

Aug 05, 2026

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 - Yahoo! Finance Canada

Aug 05, 2026

Aug 01, 2026

Enveric Biosciences (ENVB) Rallies 8.4% to $1.57 — Key Levels to WatchIceberg Order - dars.gov.et

Aug 01, 2026

Jul 28, 2026

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development - Investing News Network

Jul 28, 2026

Jul 27, 2026